Beranda › Skizofrenia › New York
Uji klinis Skizofrenia di New York
23 studi untuk Skizofrenia mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
iTBS to Enhance Social Cognition in People With Psychosis
- Zucker Hillside Hospital, Glen Oaks
Menerima peserta
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06118268Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Radial - Manhattan, New York
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Neurobehavioral Research Inc, Cedarhurst
- Evolution Research Group, Staten Island
Menerima pesertaFase 1
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07615426Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- NYU Child Study Center, New York
- Richmond Behavioral Associates, Staten Island
Menerima pesertaFase 3
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, New York
- Neurocrine Clinical Site, New York
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07114874Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, New York
- Neurocrine Clinical Site, The Bronx
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07227818A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0061, Great Neck
- Local Institution - 0156, Staten Island
- Local Institution - 0151, The Bronx
Menerima pesertaFase 3
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Adams Clinical Harlem, New York
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT0741050752-week Open Label Safety-Tolerability Study
- Neuro-Behavioral Clinical Research, New York
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0061, Great Neck
Menerima pesertaFase 3
Usia 13 hingga 17 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07288567A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, New York
- Clinical Site, Staten Island
- Clinical Site, The Bronx
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0037, Buffalo
- Local Institution - 0004, Monsey
- Local Institution - 0038, Rochester
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, New York
Menerima pesertaFase 3
Usia 10 hingga 17 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT05303064Biomarkers to Enhance Early Schizophrenia Treatment
- Feinstein Institute for Medical Research, Glen Oaks
Menerima pesertaFase 4
Usia 18 hingga 35 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06969755MicroRNAs as Biomarkers in First Episode Schizophrenia
- Zucker Hillside Hospital, Glen Oaks
Menerima pesertaSukarelawan sehat diterima
Usia 15 hingga 40 · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07703670A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
- Manhattan Psychiatric Center, New York
- NewYork-Presbyterian/Weill Cornell Medical Center Westchester Division, White Plains
Menerima peserta
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07434479Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- NYU Langone Medical Center, New York
- New York State Psychiatric Institute, New York
- Manhattan Psychiatric Center, New York
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05208190NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Staten Island
- Neurocrine Clinical Site, The Bronx
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 6 Mar 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Staten Island
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5108, New York
- Site 5077, New York
- Site 5126, White Plains
Menerima pesertaFase 2
Usia 21 hingga 55 · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT06502964Visual Perception in Schizophrenia
- University of Rochester, Rochester
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT06911931Effectiveness of Motivation Skills Training (MST)
- The Bridge, Inc., New York
- New York State Office of Mental Health, New York
Menerima peserta
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 5 Nov 2025 · NCT05805397Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
- Zucker Hillside Hospital, New York
Menerima peserta
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT05389787Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.